Sep 25th 2012 - Edison Investment Research today published a report on Evolva entitled "Trial Data And Potential Deals". In summary, the report says:
Phase IIa data on Evolva’s EV-077 indicate that it has significant potential in treating the complications of diabetes, if a safety concern can be overcome. Data from this trial and on related drugs suggest a lower dose of EV-077 should resolve the issue and still be efficacious. Promising preclinical data on the EV-035 antibacterial products could lead them to being out-licensed. Progress with the vanilla and stevia projects means they might be partnered in the next six months. We value Evolva at CHF215m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »